https://uriyablonka.com/articles/ 2026-03-31T21:52:59+00:00 https://uriyablonka.com/the-role-of-digital-biomarkers-in-agentic-clinical-trials/ 2026-03-31T22:03:02+00:00 https://uriyablonka.com/automating-safety-data-review-opportunities-and-risks-for-pharmacovigilance/ 2026-03-31T22:03:02+00:00 https://uriyablonka.com/ai-driven-compound-screening-a-new-era-for-medicinal-chemistry/ 2026-03-31T22:03:01+00:00 https://uriyablonka.com/real-world-evidence-and-agentic-ai-unlocking-post-market-insights/ 2026-03-31T22:03:01+00:00 https://uriyablonka.com/compliance-challenges-in-deploying-llms-for-regulatory-submissions/ 2026-03-31T22:03:01+00:00 https://uriyablonka.com/eu-ai-act-implications-for-pharma-a-practical-compliance-guide/ 2026-03-31T22:03:00+00:00 https://uriyablonka.com/ai-governance-in-pharma-building-accountability-frameworks/ 2026-03-31T22:03:00+00:00 https://uriyablonka.com/fdas-evolving-framework-for-ai-in-drug-development/ 2026-03-31T22:03:00+00:00 https://uriyablonka.com/rd-intelligence-competitive-analysis-through-agentic-ai/ 2026-03-31T22:02:59+00:00 https://uriyablonka.com/navigating-soc-2-compliance-for-ai-powered-pharma-platforms/ 2026-03-31T22:02:59+00:00 https://uriyablonka.com/agentic-ai-in-drug-discovery-from-target-id-to-lead-optimization/ 2026-03-31T22:02:59+00:00 https://uriyablonka.com/clinical-trial-automation-at-scale-how-ai-agents-reduce-patient-drop-off/ 2026-03-31T22:02:59+00:00